Chimerix, Inc. (NASDAQ:CMRX) insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Chimerix, Inc. (CMRX) traded up $0.03 during midday trading on Tuesday, hitting $4.45. The stock had a trading volume of 286,687 shares, compared to its average volume of 298,859. Chimerix, Inc. has a 1 year low of $4.17 and a 1 year high of $6.64.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. The company had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.81 million. research analysts forecast that Chimerix, Inc. will post -1.6 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC boosted its stake in Chimerix by 18.3% during the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 4,526 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Chimerix during the second quarter valued at approximately $185,000. The Manufacturers Life Insurance Company boosted its stake in Chimerix by 8.3% during the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 3,042 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new position in Chimerix during the first quarter valued at approximately $226,000. Finally, Alps Advisors Inc. boosted its stake in Chimerix by 5.5% during the second quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 2,178 shares during the last quarter. 70.36% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on CMRX. ValuEngine raised Chimerix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 11th. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a research note on Monday, November 13th.

ILLEGAL ACTIVITY WARNING: “Chimerix, Inc. (CMRX) Insider Sells $88,653.51 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/05/chimerix-inc-cmrx-insider-sells-88653-51-in-stock.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.